John M. Evans, CEO at Beam Therapeutics Inc. (BEAM), sold 30,000 shares at $26.75 ($803K) on 2025-01-30, disclosed to the SEC on 2025-02-03.
Scheduled sale ($803k) by CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $26.75 | 29,800 | $797K | 99.3% |
| 2 | $27.28 | 200 | $5K | 0.7% |
| Total | $26.75 avg | 30,000 | $803K | 100% |
| Filing → |
| BEAM | SELL | 2026-04-01 | $1.1M | — | Filing → |
| BEAM | SELL | 2026-02-02 | $2.8M | — | Filing → |
| BEAM | SELL | 2025-10-03 | $1.2M | — | Filing → |